ATOSSA THERAPEUTICS, INC. (ATOS): Nasdaq/NYSE listing notice — Atossa Therapeutics regains Nasdaq compliance with minimum bid price requirement

ATOSSA THERAPEUTICS, INC.

Received Nasdaq notice on July 13, 2023 that it regained compliance with Listing Rule 5550(a)(2).
Previously notified of deficiency on Oct 5, 2022; granted 180-day extension on April 4, 2023.
Met requirement by maintaining closing bid price >= $1.00 for 10 consecutive trading days through July 12, 2023.
Common stock (ATOS) will continue trading on Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 13, 2023, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 5, 2022, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was init

View on SEC.gov

Browse all listing & compliance notices →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-019877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.